Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldesleukin and Checkpoint Blockade after Radiation for Metastatic Melanoma
NCT03850691Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of aldesleukin in cutaneous melanoma (CM) and Ocular Melanoma, sponsored by Masonic Cancer Center. Started May 2019; status: completed.
02
Drugs
aldesleukin
03
Conditions
cutaneous melanoma (CM)Ocular Melanoma
Beyond the preview
Go deeper on NCT03850691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850691.